Share
in Instagram

Viral Vector Manufacturing Opportunities Across Gene Therapy, Oncology and Vaccines

Viral vector development is expanding across gene therapy, cancer treatment and vaccine research. While adeno-associated virus (AAV) vectors hold a strong position in commercial gene therapy, adenoviral, lentiviral and other vector platforms serve different therapeutic and manufacturing requirements.

For pharmaceutical companies, biotechnology developers and CDMOs, the next opportunity is not limited to increasing AAV production. It also involves identifying emerging clinical programmes, specialised manufacturing requirements and regional partnerships across multiple vector technologies.

Source: https://www.towardshealthcare.com/insights/viral-vector-manufacturing-market-sizing 

Industry Overview: AAV Leads, but the Opportunity Is Diversifying

AAV vectors are widely used in gene therapy because they can deliver genetic material into target cells and support long-term expression in selected applications. Their established role in approved gene therapies has encouraged investment in specialised manufacturing, analytical testing and GMP production capacity.

However, AAV is not suitable for every therapeutic application. Other viral vector platforms address different requirements:

  • AAV vectors: Used extensively in gene replacement and gene delivery programmes.

  • Adenoviral vectors: Used in vaccine development, cancer immunotherapy and selected gene delivery applications.

  • Lentiviral vectors: Important for ex vivo cell engineering, particularly CAR-T and other engineered cell therapies.

  • Retroviral vectors: Used in selected cell and gene therapy manufacturing programmes.

  • Oncolytic viral vectors: Designed to selectively infect and destroy cancer cells while supporting immune responses.

This technology diversity creates opportunities for manufacturers that can provide platform-specific production, process development, analytical testing and regulatory support.

Download Complete PDF Built by Industry Experts: https://www.towardshealthcare.com/download-sample/5631 

Where Are the Key Business Opportunities?

1. AAV Vectors: Established Demand for Specialised GMP Capacity

AAV remains a major commercial and clinical platform in gene therapy. Approved products such as Novartis's Zolgensma, Roche's Luxturna and Sarepta Therapeutics' Elevidys demonstrate the clinical and commercial relevance of AAV-based treatments.

However, manufacturing remains technically demanding. Developers must manage vector yield, potency, full-to-empty capsid ratios, product purity, scalability and batch consistency.

Business opportunities:

  • GMP manufacturing for clinical and commercial programmes.

  • AAV process development and scale-up.

  • Capsid engineering and analytical characterisation.

  • Empty and full capsid separation technologies.

  • Manufacturing partnerships with gene therapy developers.

Companies such as Andelyn Biosciences, Genezen and Oxford Biomedica are relevant players in the broader viral vector manufacturing ecosystem, although their platform capabilities and service offerings differ.

2. Adenoviral Vectors: Opportunities in Vaccines and Oncology

Adenoviral vectors have established applications in vaccine development and cancer research. Their ability to deliver genetic material and stimulate immune responses makes them relevant to infectious disease vaccines and selected cancer immunotherapy approaches.

The technology also provides opportunities beyond conventional vaccine production, including oncolytic virus development.

Business opportunities:

  • Adenoviral vaccine manufacturing.

  • GMP production for clinical-stage oncology programmes.

  • Viral vector engineering and process optimisation.

  • Analytical testing and quality control.

  • Partnerships with biotechnology companies developing cancer immunotherapies.

Oxford Biomedica is relevant to this opportunity because of its broader viral vector development and manufacturing capabilities. However, companies should assess its specific platform offerings rather than assume that all vector technologies are interchangeable.

3. Lentiviral Vectors: Demand from Engineered Cell Therapies

Lentiviral vectors are important tools in ex vivo cell and gene therapy manufacturing. They are frequently used to introduce genetic modifications into patient cells, including T cells used in CAR-T therapies.

Commercially established CAR-T products demonstrate the importance of this manufacturing ecosystem.

Business opportunities:

  • GMP lentiviral vector production.

  • Plasmid DNA and raw material supply.

  • Vector process development and optimisation.

  • Potency and replication-competent lentivirus testing.

  • Integrated supply agreements with cell therapy manufacturers.

CDMOs with specialised lentiviral manufacturing capabilities can target developers moving from early clinical production towards commercial-scale operations.

4. Oncolytic Viral Vectors: A Specialised Cancer Development Opportunity

Oncolytic viruses are designed to infect and destroy cancer cells and may also stimulate immune responses against tumors.

This segment creates opportunities for specialised vector engineering, manufacturing, clinical development and combination therapy research.

However, commercial development remains dependent on clinical evidence, regulatory progress and the ability to manufacture consistent products at scale.

Business opportunities:

  • GMP production for clinical-stage oncolytic virus programmes.

  • Viral engineering and characterisation.

  • Manufacturing partnerships with oncology biotechnology companies.

  • Clinical supply and analytical testing services.

5. Infectious Disease Vaccines: Opportunities Beyond Traditional Vaccine Platforms

Viral vectors remain relevant to vaccine development for infectious diseases, including HIV, malaria and tuberculosis.

Research programmes continue to investigate different vector platforms and delivery strategies. Adenoviral vectors, in particular, have been explored in several infectious disease vaccine programmes.

However, these programmes have different clinical maturity levels. Vaccine research activity should not automatically be interpreted as established commercial demand.

Business opportunities:

  • Clinical-stage vaccine manufacturing.

  • Vector development and formulation.

  • GMP production for academic and biotechnology programmes.

  • Partnerships with public health research organisations.

  • Process development for emerging infectious disease candidates.

Disease and Application Segments

Segment Strategic opportunity
Cancer CAR-T, oncolytic viruses and gene-modified cell therapies
Genetic disorders AAV-based gene replacement and gene delivery
Infectious diseases Viral vector vaccine development
Gene therapy AAV, lentiviral and other vector manufacturing
Vaccinology Adenoviral and other vector-based vaccine platforms

Cancer and infectious disease applications should be evaluated separately from gene therapy manufacturing. Lentiviral vectors, for example, have an important role in engineered cell therapies, while AAV is widely used for in vivo gene delivery.

Regional Opportunities: Where Should Manufacturers Expand?

North America: Gene Therapy Developers and GMP Manufacturing

North America remains an important region for gene therapy development, clinical research and specialised viral vector manufacturing.

The United States has a substantial ecosystem of biotechnology developers, clinical-stage programmes, academic research institutions and CDMOs.

Relevant companies include:

  • Andelyn Biosciences: Provides viral vector development and GMP manufacturing services, including AAV and lentiviral platforms.

  • Genezen: Offers viral vector development and manufacturing capabilities for gene and cell therapy programmes.

  • Thermo Fisher Scientific: Provides viral vector development and manufacturing services through its biologics and advanced therapies business.

Commercial priorities:

  • Identify clinical-stage gene therapy developers requiring GMP production.

  • Target companies transitioning from Phase I/II to later-stage clinical manufacturing.

  • Assess partnerships for analytical testing and process development.

  • Track manufacturing capacity expansion and outsourcing requirements.

Europe: Vector Manufacturing and Advanced Therapy Partnerships

The UK, Germany, France and Spain offer opportunities across biotechnology development, advanced therapy research and manufacturing partnerships.

Oxford Biomedica is a relevant European player with capabilities across lentiviral and other viral vector technologies.

Other companies and organisations across the European ecosystem provide opportunities for partnerships in process development, manufacturing, analytical services and clinical supply.

Commercial priorities:

  • Identify European gene therapy and vaccine developers.

  • Assess GMP manufacturing partnerships.

  • Track university spinouts and clinical-stage biotechnology companies.

  • Evaluate regional manufacturing requirements and cross-border supply arrangements.

Company Landscape

Company Relevant capabilities
Oxford Biomedica Viral vector development and manufacturing
Andelyn Biosciences AAV and lentiviral manufacturing
Genezen Viral vector development and GMP manufacturing
Thermo Fisher Scientific Viral vector and advanced therapy manufacturing services

These companies operate across different parts of the value chain. Their platform coverage, manufacturing scale, regulatory experience and service models should be assessed individually before identifying them as direct competitors or potential partners.

Where Are the Biggest Market Gaps?

1. GMP manufacturing capacity: Clinical-stage developers need reliable production partners as programmes progress towards larger clinical trials and commercialisation.

2. Manufacturing costs: Complex production processes, specialised raw materials and quality requirements can increase the cost of viral vector manufacturing.

3. Analytical testing: Developers need reliable methods to assess potency, identity, purity, capsid characteristics and product consistency.

4. Scale-up and batch consistency: Moving from laboratory production to commercial manufacturing remains a significant technical challenge.

5. Platform-specific expertise: AAV, adenoviral and lentiviral vectors require different production processes, equipment and analytical approaches.

6. Regional manufacturing access: Companies may seek local or regional manufacturing partners to support clinical supply, regulatory requirements and supply chain resilience.

Strategic Priorities for Manufacturers and Investors

The next phase of viral vector investment will require companies to assess more than the size of the AAV segment.

Key priorities include:

  • Diversifying vector platforms: Evaluate AAV, lentiviral, adenoviral and oncolytic vector capabilities based on therapeutic demand.

  • Building analytical expertise: Invest in potency assays, characterisation and quality control.

  • Expanding GMP services: Target developers with active clinical programmes and upcoming manufacturing requirements.

  • Developing partnerships: Collaborate with biotechnology companies, research institutes and specialised CDMOs.

  • Tracking pipeline transitions: Identify programmes approaching clinical milestones that may require new manufacturing capacity.

  • Assessing regional demand: Compare manufacturing infrastructure, regulatory requirements and biotechnology investment across North America and Europe.

How Towards Healthcare Supports Viral Vector Industry Decision-Makers

Towards Healthcare provides strategic intelligence to help biotechnology companies, CDMOs, pharmaceutical manufacturers and investors identify commercial opportunities across the viral vector ecosystem.

Our capabilities include:

  • Complete Master Datasets: Company profiles, viral vector platforms, manufacturing capabilities and pipeline intelligence.

  • Competitive Quadrants: Assessment of vector manufacturers, CDMOs and technology providers.

  • Customized Dashboards: Tracking of companies, clinical programmes, facilities and manufacturing developments.

  • Buyer Identification: Identification of gene therapy developers, vaccine companies and biotechnology organisations requiring manufacturing services.

  • GTM Strategy: Regional opportunity assessment, target account identification and partnership intelligence.

Conclusion

AAV remains a major platform in gene therapy, but the broader viral vector industry offers opportunities across adenoviral vaccines, lentiviral cell therapies and oncolytic virus development.

For manufacturers, the opportunity lies in developing specialised GMP capacity, analytical services and platform-specific expertise. For investors and biotechnology companies, tracking clinical pipelines, manufacturing requirements and regional partnerships can help identify where future demand may emerge.

Identify the companies, manufacturing partners and pipeline opportunities shaping the viral vector industry with Towards Healthcare.

About the Author

Payal Rabde

Payal Rabde

Principal Consultant

Payal Rabde is a Healthcare Market Research Analyst at Towards Healthcare Research & Consulting with 4+ years of experience in pharmaceuticals, biotechnology, medical devices, and life sciences.

Ready to Transform Your Financial Management?

We are committed to providing the best healthcare services tailored to your needs We are committed to providing the best healthcare services tailored

Financial Management